Antisense oligonucleotides selectively regulate aspartyl β-hydroxylase and its truncated protein isoform in vitro but distribute poorly into A549 tumors in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 302, Issue 2, 2002, Pages 795-803

  Ho, Siew Peng ^a   Scully, Michael S ^a   Krauthauser, Candice M ^a   Wexler, Eric J ^a   Stow, Mark D ^a   Dinchuk, Joseph E ^a   Kerr, Janet S ^a   Friedman, Paul A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ASPARTYL BETA HYDROXYLASE; GENE PRODUCT; HUMBUG; ISOPROTEIN; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SELECTIVITY; DRUG UPTAKE; ENZYME REGULATION; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RNA SPLICING; TUMOR GROWTH;

GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MIXED FUNCTION OXYGENASES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; SEQUENCE DELETION; TUMOR CELLS, CULTURED;

EID: 0036073403     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.302.2.795     Document Type: Article

References (35)

1. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues
2. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression
3. Comparative pharmacokinetics, tissue distribution, and a tumor accumulation of phosphorothioate, phosphorodithioate and methylphosphonate oligonucleotides in nude mice
4. Aspartyl β-hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin
5. Solution structure of a pair of calcium-binding epidermal growth factor-like domains: Implications for Marfan Syndrome and other genetic disorders
6. Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo
7. Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells
8. Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukemia cells
9. The product of a gas 6 splice variant allows the release of the domain responsible for Ax1 tyrosine kinase receptor activation
10. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors and remove it from low affinity binding sites on extracellular matrix
11. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries
12. RNA mapping: Selection of potent oligonucleotide sequences for antisense experiments
13. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries
14. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficiency versus herpes simplex virus infection
15. Overexpression of human aspartyl (asparaginyl) β-hydroxylase is associated with malignant transformation
16. Purification, primary structure and immunological characterization of the 26-kD calsequestrin-binding protein (junctin) from cardiac junctional sarcoplasmic reticulum
17. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides
18. Overexpression of human aspartyl(asparaginyl)β-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma
19. Anti-tumor activity of c-raf antisense - A correction
20. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
21. Invertebrate aspartyl/asparaginyl β-hydroxylase: Potential modification of endogenous epidermal growth factor-like modules
22. Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration
23. Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice
24. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo
25. Specific EGF-repeats of Notch mediate interactions with Delta and Serrate: Implications for Notch as a multifunctional receptor
26. Clearance kinetics, biodistribution and organ saturability of phosphorothioate oligodeoxynucleotides in mice
27. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate
28. 3H-labeled oligonucleotides. II. 3′,5′-blocked oligonucleotides
29. Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors
30. Molecular cloning, expression, functional characterization, chromosomal localization and gene structure of junctate, a novel integral calcium binding protein of sarco(endo)plasmic reticulum membrane
31. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
32. Tumor biology: Use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments
33. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis
34. Structural alterations in cardiac calcium release units resulting from overexpression of junctin
35. Complex formation between junctin, triadin, calsequestrin and the ryanodine receptor